Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Consensus Target Price of $38.29 According to Brokerages

Vor Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly bullish: Vor Biopharma has a consensus “Buy” rating from nine firms, with a 12-month average price target of $38.29. Ratings include five buys, two strong buys, and two holds.
  • Quarterly results fell short of expectations: Vor reported a loss of $1.45 per share, versus the consensus estimate of a $0.81 loss. Analysts expect a loss of $2.74 per share for the current year.
  • Institutional investors and hedge funds own 97.29% of the stock; several firms recently increased or initiated positions.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) have been assigned an average recommendation of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $38.29.

A number of brokerages recently commented on VOR. Wall Street Zen cut shares of Vor Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, October 31st. Citigroup upgraded shares of Vor Biopharma to a "strong-buy" rating in a research note on Thursday, October 15th. William Blair assumed coverage on shares of Vor Biopharma in a report on Wednesday, October 21st. They set an "outperform" rating on the stock. Weiss Ratings raised shares of Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, September 14th. Finally, Stifel Nicolaus set a $40.00 target price on Vor Biopharma in a research report on Monday, November 2nd.

View Our Latest Report on VOR

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of VOR. Global Retirement Partners LLC lifted its position in Vor Biopharma by 40.3% in the 3rd quarter. Global Retirement Partners LLC now owns 2,931 shares of the company's stock worth $56,000 after buying an additional 842 shares during the last quarter. Parallel Advisors LLC grew its position in Vor Biopharma by 29,640.0% during the third quarter. Parallel Advisors LLC now owns 1,487 shares of the company's stock valued at $28,000 after acquiring an additional 1,482 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Vor Biopharma by 25.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company's stock valued at $198,000 after acquiring an additional 2,171 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Vor Biopharma during the third quarter valued at approximately $58,000. Finally, Fulcrum Asset Management LLP purchased a new position in shares of Vor Biopharma during the third quarter worth approximately $64,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Stock Down 2.3%

Shares of VOR stock opened at $18.97 on Tuesday. Vor Biopharma has a 52-week low of $6.50 and a 52-week high of $26.00. The company has a 50-day simple moving average of $19.87 and a two-hundred day simple moving average of $17.55.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.64). Equities research analysts predict that Vor Biopharma will post -2.74 earnings per share for the current year.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.

See Also

Analyst Recommendations for Vor Biopharma (NASDAQ:VOR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vor Biopharma Right Now?

Before you consider Vor Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.

While Vor Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines